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Abstract. Prostate cancer is the second leading cause of 
male-cancer related death in the United States. Despite a 
number of evidence-based studies which strongly suggest an 
association between cigarette smoking and prostate cancer, 
the underlying biological mechanism is largely unknown. 
Heme oxygenase 1 (HO-1) has been implicated in maintaining 
cellular homeostasis, but also in tumor angiogenesis. Nuclear 
HO-1 protein expression has been observed in various types of 
tumors including prostate cancer. These studies, however, were 
reported as clinical and pathological observations, and failed to 
investigate nuclear HO-1 at the molecular level in cancer. The 
present study explores the relationship between cigarette smoke 
and nuclear HO-1-modulated promotion of vascular endothe-
lial growth factor (VEGF) secretion. We have demonstrated 
that cigarette smoke medium (SM)-induced HO-1 mRNA 
expression and upregulated HO-1 protein levels in the prostate 
cancer cell lines DU145 and PC3. We also observed that SM 
significantly induced nuclear expression of HO-1, and enhanced 
secretion of VEGF in cells. Nuclear-directed expression of HO-1 
activated the transcriptional activity of VEGF and promoted 
VEGF secretion in prostate cancer cells. This study provides 
new insights into the molecular mechanism by which cigarette 
smoke-induced nuclear translocation of HO-1 promotes VEGF 
secretion in prostate cancer cells. Nuclear HO-1 may, therefore, 
constitute an attractive therapeutic target to inhibit angiogenesis 
and the progression of prostate cancer.
Introduction
Prostate cancer is the second leading cause of male-malignancy-
related death in the United States (1). A growing body of data 
indicates that the initiation and progression of prostate cancer 
is influenced by aging, genetic predisposition, environmental 
factors such as toxins, and lifestyle choices such as cigarette 
smoking. Cigarette smoking has been identified as the most 
preventable cause of cancer morbidity and mortality, yet, 20% of 
US adult males were reported to be cigarette smokers in 2010 (2).
The combustion product of cigarettes is an aerosol 
containing more than 3,500 chemical compounds, many of 
which have been shown to be carcinogens or mutagens. Smoke 
generated from burned cigarettes consists of a particulate solid 
phase (tar) and a gaseous phase containing volatile organic 
compounds, free radicals and other volatile and semi-volatile 
compounds (3,4). The water-soluble components of aqueous 
cigarette tar can produce the superoxide anion (O2•-) and subse-
quently hydrogen peroxide (H2O2) and the reactive hydroxyl 
radical (HO•), which can cause oxidative stress damage to 
membrane lipids, proteins and DNA (4), contributing to inflam-
mation and cancer. Active and passive exposure to products of 
cigarette combustion promotes angiogenesis and malignancy of 
the prostate, lung, esophagus, bladder, pancreas and cervix (5). 
Cigarette smoking has also been linked to an elevated risk of 
advanced stage and high-grade prostate cancer, both of which 
are indicative of a poor prognosis (6). Although much is known 
about the epidemiology of cigarette smoking, the underlying 
cellular and molecular mechanisms responsible for its carcino-
genic potential in prostate cancer remain unclear.
Heme oxygenase (HO) is a microsomal rate-limiting enzyme 
involved in the degredation of heme (7,8). The three mamma-
lian isoforms of heme oxygenase, HO-1, HO-2 and HO-3, have 
distinct patterns of tissue-specific expression (9). HO-1, also 
known as heat shock protein 32 (HSP-32), is highly expressed in 
the spleen and liver, and at lower levels in several other mamma-
lian tissues (10,11) has been implicated in maintaining cellular 
homeostasis, reducing oxidative stress damage, attenuating the 
inflammatory response, inhibiting apoptosis and regulating 
proliferation (12). Conversely, HO-1 is also recognized as an 
important proangiogenic mediator (13). HO-1 expression is 
elevated in various cancer cells (14-17) and tumors (18-20). 
Ectopic expression of HO-1 has been shown to increase VEGF 
secretion and enhance VEGF-mediated activities such as prolif-
eration and migration, leading to improved formation and growth 
of capillary-like tubular structures (21,22) as well as tumor 
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angiogenesis in a mouse model of pancreatic cancer (21-23). 
Endothelial cells deficient in HO-1 secrete less VEGF than their 
wild-type counterparts. Reducing HO-1 expression or inhibiting 
its enzymatic activity impairs vGPCR-enhanced survival and 
VEGF-A expression in endothelial cells (24), and inhibits VEGF 
expression in lung carcinoma (25,26).
A number of cohort studies suggest that cigarette smoking 
may be associated with prostate cancer (6), however, the 
molecular mechanism(s) linking it to prostate cancer remain 
elusive. Nuclear HO-1 protein expression has been observed 
in various tumors (27-29) including prostate cancer (19). 
These studies, however, were reported as clinical and patho-
logical observations, and failed to investigate role of nuclear 
HO-1 expression molecularly in prostate cancer. The present 
study explored the relationship between cigarette smoke and 
nuclear expression of HO-1 and to investigate molecular 
mechanism(s) by which cigarette smoke-induced nuclear 
translocation of HO-1 promoted VEGF secretion in prostate 
cancer cells. The present study demonstrated cigarette smoke 
induced nuclear translocation of HO-1 in prostate cancer cells. 
Nuclear-directed expression of HO-1 increased transcriptional 
activity and secretion of VEGF in prostate cancer cells. The 
data revealed that cigarette smoke-mediated translocation of 
HO-1 was associated with increased VEGF secretion, and also 
suggested that exposure to first- and secondhand products of 
cigarette combustion were associated with prostate cancer via 
nuclear HO-1-modulated VEGF secretion.
Materials and methods
Reagents. Anti-4-hydroxy-2-nonenal (anti-4-HNE) anti-
body (cat. 24325) was purchased from Percipio Biosciences 
(Burlingame, CA). Anti-GAPDH (cat. sc-137179), anti-lamin B1 
(cat. Sc-56144) and anti-GFP (cat. sc-8334) antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-HO-1 antibody (cat. ADI-SPA-895-F) was purchased 
from Enzo Life Sciences (Ann Arbor, MI). Titanium One-Step 
RT-PCR kit (cat. 639503) was purchased from Clontech 
(Mountain View, CA). Human VEGF ELISA kit (cat. DVE00) 
was purchased from R&D Systems (Minneapolis, MN). NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (cat. 78833) were 
from Thermo Scientific (Rockford, IL). CellTiter 96 Aqueous 
non-radioactive cell proliferation assay kit (cat. G5421) was 
purchased from Promega Corporation (Madison, WI).
Cells and culture conditions. The prostate carcinoma cell line 
DU145 (cat. HTB-81) was obtained from the American Type 
Culture Collection (Manassas, VA) and cultured in Eagle's 
minimum essential medium (Mediatech Inc., Manassas, VA) 
supplemented with 10% FBS. The prostate adenocarcinoma cell 
line PC3 (cat. CRL-1435) was also obtained from the American 
Type Culture Collection and cultured in DMEM F-12 50/50 
medium (Mediatech Inc.), supplemented with 10% FBS. COS-7 
and HEK293T cells were cultured in Dulbecco's modified 
Eagle's medium (Mediatech Inc.) containing 10% FBS. All cells 
were maintained at 37˚C, in a 5% CO2 incubator.
Cigarettes and the preparation of smoke medium. 3R4F refer-
ence cigarettes were purchased from the Reference Cigarette 
Program, University of Kentucky (Lexington, KY). Federal 
Trade Commission Smoking analysis indicated that 3R4F 
cigarettes contained 11.0 mg/cigarette (mg/cig) total particulate 
matter (TPM), 9.4 mg/cig of tar, 0.73 mg/cig nicotine, and 
12 mg/cig carbon monoxide. Smoke media (SM) was generated 
by collecting whole smoke from burning one pack (20 ciga-
rettes) of reference cigarettes into 100 ml of cell culture media. 
SM was filtered and stored at -80˚C for further use.
Cell proliferation assay. The assay was performed using a 
CellTiter 96 Aqueous non-radioactive cell proliferation assay 
kit per manufacturer's instruction. Briefly, 100 μl of DU145 and 
PC3 (5x104 cells) cell suspension were grown on 96-well plates 
incubated at 37˚C and 5% CO2. After 24 h, the culture medium 
was either refreshed or replaced with serial dilutions of SM as 
indicated. The accumulation of formazan was measured spec-
troscopically by absorption at 490 nm.
RNA isolation. Isolation of total RNA was performed using 
TRIzol Reagent (Life Technologies, Carlsbad, CA) according 
to the manufacturer's instructions. Briefly, cells were seeded 
on 6-well plates and treated with SM or standard cell culture 
media. A total of 1.0 ml of TRIzol was added followed by 
0.2 ml of chloroform after 15 min. Samples were vigorously 
inverted by hand for 15 sec, incubated at room temperature for 
3 min and centrifuged at 12,000 x g for 15 min at 4˚C. After 
centrifugation, 0.5 ml of isopropanol was added to the superna-
tant. After incubation at room temperature for 10 min, samples 
were centrifuged at 12,000 x g for 10 min at 4˚C. The pellets 
were washed with 75% ethanol, dissolved in RNAse-free water 
and incubated for 10 min at 60˚C. RNA concentration was 
measured and the samples were stored at -80˚C.
RT-PCR Analyses. RNA transcript levels were semi-quantified 
using the Titanium One-Step RT-PCR kit (Clontech) according 
to the manufacturer's instructions using the forward 
5'-GAGACGGCTTCAAGCTGGTGATG-3' and reverse 
5'-GTTGAGCAGGAACGCAGTCTTGG-3' primers for HO-1, 
and the forward 5'-GAAGGTGAAGGTCGGAGTC-3' and 
reverse 5'-GAAGATGGTGATGGGATTTC-3' primers for 
GAPDH. The conditions were one cycle of 50˚C for 1 h and 
94˚C for 5 min, followed by 25 cycles of 94˚C for 30 sec, 68˚C 
for 30 sec and 68˚C for 60 sec with an extension of 68˚C for 
2 min. The RT-PCR products were visualized on 1% agarose 
gels stained with ethidium bromide and quantified by Scion 
Image Software.
Immunoblot analysis. Cells were washed with PBS and lysed 
directly on ice with RIPA buffer. The lysates were transferred 
to a new tube, solubilized for 1 h at 4˚C and clarified by 
centrifugation at 12,000 rpm for 20 sec at 4˚C. Total cell extract 
protein concentration was determined by Bradford assay. 
Equal amounts of proteins were loaded and electrophoresed on 
SDS-PAGE gels, blotted onto PVDF membrane and incubated 
with anti-HO-1 and anti-GAPDH antibodies. Blots were washed 
3 times and incubated with a HRP-conjugated IgG antibody. 
Protein expression was detected on X-ray films and quantified 
using Scion Image Software.
Immunohistochemistry. Cell cultures were washed twice 
with PBS, fixed with 4% paraformaldehyde and treated with 
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0.5% Triton X-100 in PBS for 30 min. After 3 washes with PBS, 
cells were treated with PBS containing 10% goat serum for 2 h 
and incubated with anti-4HNE antibodies for 24 h at 4˚C. After 
3 washes with PBS, the cells were incubated with FITC- and/or 
TRITC-conjugated IgG antibodies for 1 h at room temperature. 
The cells were then washed, mounted on slides and imaged 
using a Zeiss LSM510 Meta confocal microscope.
Generation of DNA constructs. pEGFP-HO-1 (HO-1 fused 
with the C-terminus to EGFP) was created by PCR amplifica-
tion of HO-1 cDNA using the forward primer 5'-CAGCGAATTC 
ACCATGGAGCGTCCGCAACCCGACAGC-3' containing 
an EcoRI restriction site and the reverse primer 5'-GAT 
GGATCCCGATGCGGCCGCCATGGCATAAAGCCCTAC-3' 
containing a BamHI site. The product was ligated into the 
pEGFP-N3 vector at the EcoRI and BamHI sites. Similarly, 
pEGFP-HO-1/NLS (same as pEGFP-HO-1, but containing 
tandem nuclear localization signals between HO-1 and EGFP) 
was created by PCR amplification of the pNuc-HO-1 template 
(described below) using the same forward primer as above and 
the reverse primer 5'-CTGGGATCCCTACCTTTCTCTTC 
TTTTTTGGATCTACCTTTCTCTTC-3' containing a BamHI 
site. The product was inserted into pEGFP-N3 at the unique 
EcoRI and BamHI restriction sites.
pFlag-HO-1 (HO-1 with an N-terminal FLAG-tag) was 
created by PCR amplification of the HO-1 cDNA using the 
primers 5'-CAAGCTTGAGCGTCCGCAACCCGACAGC-3' 
and 5'-CGGATCCTCATTACATGGCATAAAGCCC-3', and 
insertion into the pFlag-CMV4 vector at the HindIII and 
BamHI sites. pNuc-HO-1 (HO-1 with tandem nuclear localiza-
tion at the C-terminus) was generated by PCR amplification 
using the primers 5'-TAGTCGACGAGCGTCCGCAACCC 
GAC-3' and 5'-TAGCGGCCGCCATGGCATAAAGCCCT-3' 
and insertion into the pCMV/myc/nuc vector at SalI and NotI 
restriction sites. Expression in HEK293T cells was confirmed 
by immunoblot analysis using an anti-HO-1 antibody.
Luciferase assay. HEK293T or COS7 cells were co-transfected 
with combinations of plasmids as indicated in the figure 
legends using Lipofectamine reagent (Life Technologies). Cell 
lysates were prepared and luciferase and β-galactosidase activi-
ties were quantified using a Luciferase assay kit (Promega) 
according to the manufacturer's instructions. The effect of 
the transfected proteins on promoter transcriptional activity 
was assessed by measuring luciferase activity normalized to 
β-galactosidase activity.
Statistics. Statistical significance was determined using the 
Student's t-test and one-way ANOVA. Data represent the 
mean ± SD of independent experiments, with a p<0.05 consid-
ered statistically significant.
Results
Effect of cigarette smoke on growth of prostate cancer cells. 
Many epidemiological research studies have shown that cigarette 
smoking is linked to aggravation of cancer progression. Here, 
we examined the concentration of cigarette smoke medium 
which supported the growth of prostate cancer cells. Cigarette 
smoke medium (SM) was prepared as described in Materials and 
methods. Concentrations of total particulate materials (TPM), 
tar, nicotine (Nico) and carbon monoxide (CO) in SM were 
estimated from the Federal Trade Commission Smoking 
analysis as described in Materials and methods and indicated 
in Fig. 1. PC3 cells were plated onto 96-well plates containing 
10% FBS culture medium. After 24 h, the cell culture medium 
was replaced with culture medium containing 0.5% FBS. After a 
further 24 h, cell cultures were treated with serial dilutions of SM 
ranging from 0.5-2% (v/v), for 48 h, as indicated in Fig. 1. Cell 
proliferation was assessed using the CellTiter Non-Radioactive 
Cell Proliferation Assay, known as MTS. Treatment with 0.5 and 
1% SM significantly promoted growth of PC3 cells, however, 
2% SM did not appear to have a significant inhibitory effect 
on cell proliferation (Fig. 1). SM (4, 10 and 20%) inhibited cell 
growth (data not shown). SM supported the growth of PC3 cells 
in a dose-dependent manner, in particular, SM (0.5%). SM (0.5%) 
in cell culture media was used for further studies.
Cigarette smoke induced expression of HO-1 in prostate cancer 
cells. Next, we examined whether SM induces expression of 
HO-1 in DU145 and PC3 cells. For this study, cells were treated 
for 0, 3 and 6 h with 0.5% SM. Steady state transcript levels of 
HO-1 and GAPDH (internal control) were assessed by semi-
quantitative PCR analysis. HO-1 transcript levels increased in 
0.5% SM-treated DU145 and PC3 cells in a time-dependent 
manner (Fig. 2A and B). HO-1 mRNA levels were 1.7- and 
1.9-fold higher in DU145 and 1.5- and 2.0-fold higher in PC3 
cells after 3 and 6 h of 0.5% SM treatment, respectively (Fig. 2A 
and B). These results suggested that HO-1 plays a central role in 
the response to SM exposure in prostate cancer cells.
Figure 1. Effect of cigarette smoke on growth of prostate cancer cells. PC3 
cells were plated onto 96-well plates and starved with culture medium 
containing 0.5% FBS. After 24 h, cell cultures were treated with serial dilu-
tions of SM (2, 1 and 0.5%) as indicated. Concentrations of total particulate 
matter (TPM), tar, nicotine (Nico) and carbon monoxide (CO) were estimated 
based on information provided by the reference cigarette program. A CellTiter 
Non-Radioactive Cell Proliferation Assay was performed after 24 h, to deter-
mine effect of SM on cell growth. Growth rate was expressed as absorbance of 
the formazan product at 490 nm. Columns, mean; bars, SD; *p<0.05; **p<0.01.
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To further analyze the effect of SM on activation of 
HO-1, DU145 and PC3 cells were treated with SM for 24 h 
and expression of HO-1 was determined by western blot 
analyses. Cell extracts of DU145 and PC3 cells treated with 
0.5% SM for 0 and 24 h were prepared and protein expression 
was determined by western blot analysis using an anti-HO-1 
antibody. Expression of HO-1 (normalized to GAPDH) was 
significantly higher in SM treated cells compared to controls 
(Fig. 2C and D). HO-1 expression was 2.1-fold (p=0.047) 
higher in DU145 cells and 2.0-fold (p=0.002) higher in PC3 
cells after 24 h of 0.5% SM treatment compared to controls 
(0 h of treatment). Relative levels of HO-1 expression were 
determined based on data derived from three independent 
experiments (Fig. 2C and D). These finding indicated that 
0.5% SM induced steady-state HO-1 mRNA and protein levels 
in DU145 and PC3 cells.
Figure 2. Cigarette smoke induced expression of HO-1 in prostate cancer cells. (A and B) SM induced mRNA levels of HO-1 in prostate cancer cells. DU145 and 
PC3 were treated with SM for 0, 3 and 6 h. Total RNA was isolated and analyzed by semi-quantitative RT-PCR using primers for HO-1 and GAPDH (internal 
control). Relative HO-1 mRNA levels derived from three individual experiments were expressed in arbitrary units. Columns, mean; bars, SD; *p<0.05; **p<0.01. 
(C and D) SM increased HO-1 protein levels in prostate cancer cells. (C) DU145 and (D) PC3 cells were grown on 6-well plates and treated with SM for 0 and 
24 h. Cell extracts were subjected to western blot analysis using anti-HO-1 and anti-GAPDH antibodies. GAPDH served as an internal control. Relative HO-1 
protein levels derived from three individual experiments were expressed in arbitrary units. Columns, mean; bars, SD; *p<0.05; **p<0.01.
INTERNATIONAL JOURNAL OF ONCOLOGY  42:  1919-1928,  2013 1923
Cigarette smoke induced VEGF secretion in prostate cancer 
cells. VEGF has been implicated in tumor progression and 
expression of VEGF has been reported in a number of cell 
lines and clinical specimens derived from a broad range of 
cancers (30-33). Here we examined whether exposure to SM 
stimulated VEGF secretion in prostate cancer cells. DU145 and 
PC3 cells were grown in culture medium supplemented with 
10% FBS. After 24 h, cells were refreshed with culture medium 
containing 0.5% FBS, and then treated with 0.5% SM for 0 and 
24 h. Cell culture supernatants were collected after 0 and 24 h, 
and VEGF secretion was assessed by ELISA per the manufac-
turer's instructions. VEGF increased 1.65-fold (p=0.0002) in 
DU145 cells (Fig. 3A) and 4.38-fold (p=0.0002) in PC3 cells 
(Fig. 3B) after 24 h treatment with SM. These results suggested 
that SM induced VEGF secretion in prostate cancer cells.
Cigarette smoke induced nuclear translocation of HO-1 in 
prostate cancer cells. Recent studies reported that nuclear 
localization of HO-1 was associated with prostate cancers (19), 
and head and neck squamous cell carcinomas (27). Treatment 
of DU145 and PC3 cells with SM induced mRNA and protein 
levels of HO-1 as compared to control counterparts (Fig. 2). We 
examined whether SM induced nuclear translocation of HO-1 in 
DU145 and PC3 cells. Cellular fractionation was performed to 
determine the cellular distribution of HO-1 in SM-treated and 
untreated cells. DU145 and PC3 cells were treated with either 
culture medium or 0.5% SM and cellular fractions were blotted 
with anti-HO-1, anti-GAPDH (cytoplasmic maker) or anti-lamin 
B1 (nuclear marker) antibody after 24 h. The level of cytoplasmic 
HO-1 was significantly higher in SM-treated DU145 and PC3 
cells compared to their control counterparts (Fig. 4A and B).
We also observed that levels of HO-1 in the nuclear fraction 
significantly increased in DU145 and PC3 cells treated with SM 
compared to untreated controls (Fig. 4A and B). For quantifica-
tion purposes, expression of nuclear HO-1 was normalized to 
that of lamin B1 and expressed in arbitrary units. Data were 
averaged from three independent experiments. Relative levels 
of nuclear HO-1 were 1.37-fold (p=0.001) higher in DU145 cells 
and 2.65-fold (p=0.01) higher in PC3 cells treated with 0.5% SM 
compared to controls (Fig. 4C and D).
Nuclear-directed expression of HO-1 in HEK293 cells. SM 
increased cytoplasmic expression and nuclear translocation of 
HO-1 in prostate cancer cells (Fig. 4). SM-mediated expression 
of HO-1 also correlated with an increase in VEGF secretion 
(Fig. 3). These observations prompted us to investigate the role 
of cytoplasmic and nuclear HO-1 in the regulation of VEGF. 
For this study, we generated two constructs by fusing HO-1 and 
HO-1 with C-terminal nuclear localization signals (NLS) to the 
N-terminus of EGFP. The generated constructs were designated 
pEGFP-HO-1 and pEGFP-HO-1/NLS. HEK293 cells were 
transfected and stained with F-actin (cytoplasmic marker) 
and DAPI (nuclear marker). As anticipated, cells transfected 
with pEGFP-HO-1 expressed HO-1 exclusively in the cytosol 
(Fig. 5A), whereas cells transfected with pEGFP-HO-1/NLS 
expressed HO-1/NLS exclusively in the nucleus (Fig. 5B), 
demonstrating that a carboxyl terminal NLS could efficiently 
mediate nuclear expression of HO-1 in vitro (Fig. 5B). Exclusive 
expression of HO-1/NLS in the nucleus can therefore be used to 
examine the function of nuclear HO-1 in vitro, thus mimicking 
endogenous HO-1 in prostate cancer tissues as shown previously 
(19,33). Furthermore, this system can be used to compare func-
tion of cytoplasmic and nuclear HO-1 in VEGF transcriptional 
activation and secretion.
Nuclear localization of HO-1 promoted transcriptional 
activity of VEGF. Next, we generated two constructs of 
HO-1, pFlag-HO-1 (HO-1 with N-terminal FLAG-tag) and 
pNuc-HO-1/NLS (HO-1 with C-terminal NLS). We then 
assessed whether cytoplasmic or/and nuclear expression of HO-1 
enhanced transcriptional activity of VEGF. HEK293 cells were 
co-transfected with the VEGF promoter (pVEGF) and either 
pFlag-HO-1 (cytoplasmic HO-1) or pNuc-HO-1/NLS (nuclear 
HO-1) in a dose-dependent manner (Fig. 6A). Cell extracts were 
prepared after 24 h, and luciferase activity normalized to β-Gal 
activity was assayed to measure VEGF promoter activity. The 
Figure 3. Cigarette smoke induced VEGF secretion in prostate cancer cells. (A) DU145 and (B) PC3 cells were grown in complete culture medium. Cells were 
refreshed with culture medium containing 0.5% FBS for 24 h, and then treated with SM. Culture supernatants were collected and cells were counted after 24 h. 
VEGF concentration was determined by ELISA and expressed as pg/104 cells. Micrographs are representative of three individual experiments. Columns, mean; 
bars, SD; *p<0.05; **p<0.01.
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Figure 4. Cigarette smoke induced nuclear translocation of HO-1 in prostate cancer cells. (A) DU145 and (B) PC3 cells were grown on 6-well-plates and treated 
with SM. After 24 h, cellular fractionation was performed, and the cytoplasmic and nuclear fractions were analyzed by western blotting using an anti-HO-1 
antibody. The blots were re-probed with anti-GAPDH or anti-Lamin B1 antibodies. (C) DU145 and (D) PC3 cells were treated with SM. Nuclear extracts were 
probed with anti-HO1 and Lamin B1 antibodies. Nuclear expression of HO-1 was normalized to that of the nuclear marker Lamin B1, and relative expression of 
nuclear HO-1 was expressed in arbitrary units. Data shown in micrographs were derived from three individual experiments. Columns, mean; bars, SD; **p<0.01. 
CTL, control; CE, cytoplasmic extract; NE, nuclear extract.
Figure 5. Nuclear-directed expression of HO-1 in HEK293 cells. HO-1 and HO-1/NLS were constructed into pEGFP-N3 vector. Resultant constructs, 
(A) pEGFP-HO-1 and (B) pEGFP-HO-1/NLS, were transfected in HEK293 cells. After 24 h, cells were fixed and stained with F-actin phalloidin and DAPI. 
Images were taken by using Zeiss LSM 510 Meta confocal microscope. Bar, 50 µm.
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expression levels of HO-1 were determined by western blot 
analysis with anti-HO-1 antibody. Membranes were stripped 
and reblotted with an anti-GAPDH antibody to ensure equal 
loading. Relative VEGF promoter activity was approximately 
6-fold higher in cells transfected with pNuc-HO-1 and approxi-
mately 3-fold higher in cells transfected with pFlag-HO-1 
compared to their control counterparts (Fig. 6A).
HEK293 and COS7 cells were cotransfected with the 
VEGF promoter (pVEGF) and either pNuc-HO-1/NLS [HO-1, 
also known as Heat Shock Protein 32  (10)] or pEGFP-HSP72 
(HSP72, heat shock protein 72) as a control in a dose-dependent 
manner. Cell extracts were prepared after 24 h and a luciferase 
assay was performed to measure VEGF promoter activity. 
Luciferase activity was normalized and expressed in arbitrary 
units relative to β-Gal activity. Expression levels of HO-1 and 
HSP72 were determined by western blot analysis with anti-HO-1 
and anti-GFP antibodies. Blotting with anti-GAPDH antibody 
demonstrated equal loading of cell extracts. Relative luciferase 
activity was upregulated in a dose-dependent manner in cells 
transfected with HO-1/NLS, whereas luciferase activity was 
Figure 6. Nuclear localization of HO-1 promoted transcriptional activity of VEGF. (A) Differential activation of VEGF transcriptional activity by cytoplasmic 
and nuclear HO-1. HEK293 cells were co-transfected with the VEGF promoter and HO-1 or HO-1/NLS in a dose-dependent fashion, as indicated. After 24 h, 
VEGF promoter activity (luciferase activity) was measured and normalized to β-Gal activity. Relative VEGF promoter activity derived from three experiments 
was expressed in arbitrary units. Cell extracts were also blotted with anti-HO-1 and anti-GAPDH antibodies. Columns, mean; bars, SD; *p<0.05; **p<0.01. pVEGF, 
VEGF promoter; HO-1, plasmid expressing HO-1 in cytosol; HO-1/NLS, plasmid expressing nuclear HO-1; NLS, nuclear localization signal. (B) Differential 
activation of VEGF transcriptional activity by heat shock proteins. HEK293 and COS7 cells were co-transfected with the VEGF promoter and pNuc-HO-1/NLS or 
EGFP-HSP72 in a dose-dependent manner as indicated. After 24 h, luciferase activity was measured and normalized to β-galactosidase (β-Gal) activity to quantify 
VEGF promoter activity. Relative VEGF promoter activity was expressed in arbitrary units. Micrograph is representative of three independent experiments. Cell 
extracts were also blotted with anti-HO-1, anti-GFP and anti-GAPDH antibodies. GAPDH served as internal control. Columns, mean; bars, SD; *p<0.05; **p<0.01. 
HO-1, also known as heat shock protein 32; and HSP72, heat shock protein 72; NLS, nuclear localization signal. Upper panel: HEK293; lower panel: COS7.
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relatively unchanged in cells transfected with GFP-HSP72 
(Fig. 6B). VEGF promoter activity was 2.60-fold (p<0.001) and 
5.7-fold (p<0.001) higher in HEK293T cells transfected 0.2 and 
0.4 µg of pNuc-HO-1/NLS, respectively (Fig. 6B), and 4.61-fold 
(p<0.001) and 6.47-fold (p<0.001) higher when COS7 cells 
which were similarly cotransfected. In contrast, transfection of 
HEK293 and COS7 cells with GFP-HSP72 had no statistically 
significant effect on luciferase activity (Fig. 6B). These results 
showed that nuclear HO-1 significantly increased transcriptional 
activity of the VEGF promoter in a dose-dependent manner, 
while HSP72 had an insignificant effect on the activity of the 
VEGF promoter (Fig. 6B). These findings suggested that nuclear 
expression of HO-1 plays an important role in the transcriptional 
activity of VEGF.
Ectopic expression of nuclear HO-1 promoted VEGF secretion 
in prostate cancer cells. Given that ectopic expression of nuclear 
HO-1 increased VEGF promoter activity (Fig. 6), we sought to 
further examine the effect of nuclear HO-1 on VEGF secretion 
using ELISA. For this analysis, PC3 cells were used because 
of their high transfection efficiency. PC3 cells were transfected 
with mock, pFlag-HO-1 or pNuc-HO-1/NLS. Cell cultures 
were washed and replaced with fresh medium containing 
0.5% FBS within 24 h. Cell culture supernatants were collected 
and analyzed for VEGF using ELISA. Ectopic expression of 
HO-1/NLS significantly enhanced VEGF secretion compared 
to cells transfected with HO-1 (Fig. 7A). Next, cell cultures 
were replaced with fresh medium containing 0.5% FBS and 
then treated with SM for 24 h. Supernatants were collected and 
VEGF concentration was measured by ELISA. A significant 
increase in VEGF secretion was observed in cells transfected 
with HO-1/NLS compared to cells transfected with mock or 
HO-1 (Fig. 7B). These data suggested that nuclear HO-1 was 
involved in promoting VEGF secretion.
Discussion
Cigarette smoking represents one of the most serious prob-
lems for public health, and at present accounts for 6 million 
deaths annually worldwide (34). Although the relevance of this 
epidemic is known, the molecular mechanism(s) underlying its 
toxicity and carcinogenic potential remain elusive. Cigarette 
smoking has been linked to cancers of the lung, breast and 
brain (34), but while some research studies have shown that 
cigarette smoking is not associated with the incidence of 
prostate cancer, other reports suggested that current or recent 
cigarette smoking is linked to an elevated risk of mortality, 
advanced stage or high-grade disease (6). Cigarette smoking 
may therefore be involved in the progression rather than the 
initiation of prostate cancer. A number of studies demonstrated 
that angiogenesis is associated with the progression of prostate 
cancer (31,32). Previous reports detected higher levels of HO-1 
protein in various tumor tissues compared to normal tissue 
(33,35-40), and was associated with tumor progression of 
head and neck squamous cell carcinomas (27). The angiogenic 
cytokine VEGF has a central role in tumor angiogenesis by 
binding and activating the receptors, VEGFR1 and VEGFR2. 
The VEGF/VEGFR axis promotes endothelial cell differentia-
tion, cell growth, tubular formation and migration (41-45). It 
has also been reported that HO-1 is an important proangio-
genic mediator, which further supports tumor progression (12). 
The present study explores the relationship between cigarette 
smoke, HO-1 expression and VEGF secretion in prostate 
cancer cells.
In response to oxidative stress, cells have evolved multiple 
protective mechanisms to neutralize and clear toxic molecules 
and restore cellular redox homeostasis. Induction of HO-1 is a 
fundamental cellular defense process against oxidative stress 
caused by environmental stimuli. Cells lacking HO-1 are 
Figure 7. Ectopic expression of nuclear HO-1 promoted VEGF secretion in prostate cancer cells. (A) PC3 cells were transfected with mock, HO-1 or HO-1/NLS. 
After 24 h, cells were starved with cell culture medium containing 0.5% FBS. After 24 h, supernatants were collected, and VEGF secretions were measured by 
using ELISA. Columns, mean; bars, SD; *p<0.05; **p<0.01. (B) Cell culture, in (A), then were replenished with cell culture medium containing 0.5% FBS plus SM. 
After 24 h, supernatants were collected and VEGF secretions were measured by using ELISA. Columns, mean; bars, SD; *p<0.05; **p<0.01.
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susceptible to free radical damage and oxidative injury, which 
results in high levels of endothelial damage and prolonged 
inflammation (10,11). Treatment with SM induced HO-1 
mRNA expression and increased HO-1 protein in prostate 
cancer cells (Fig. 2). Induction of HO-1 may therefore provide 
the first line of cellular defense of prostate cancer cells against 
the oxidative stimulus of cigarette smoke. Thus, an increase in 
HO-1 levels may be required for survival of prostate cancer 
cells. This result is consistent with previous analyses of 
HO-1 expression in different types of cancer. Overexpression 
of HO-1 has been reported in lymphosarcoma (35), brain 
tumors (36), renal carcinoma (37), hepatoma (38), Kaposi 
sarcoma (39), pancreatic cancer (40) and chronic myeloid 
leukemia (41). Cigarette smoking has been shown to be asso-
ciated with an elevated risk of mortality or advanced stage 
prostate cancer, but not with incidence of prostate cancer (6). 
These lines of evidence strongly suggest that SM-mediated 
induction of HO-1 may be associated with the progression of 
prostate cancer.
HO-1 has been reported to promote VEGF secretion and 
facilitate VEGF-mediated activities such as promoting the 
efficiency of cell proliferation and migration and improving 
the formation of capillary-like tubular structures and capil-
lary outgrowth (14,15). Treatment of prostate cancer cells 
with SM induced expression of HO-1 (Fig. 2) and enhanced 
VEGF secretion in both DU145 and PC3 cells (Fig. 3). Ectopic 
expression of HO-1 (also known as heat shock protein 32) and 
another heat shock protein, HSP72 were tested for their ability 
to induce VEGF transcriptional activity. While HSP72 failed 
to increase transcriptional activity of VEGF, HO-1 induced 
significant transcriptional activity of VEGF (Fig. 6) and VEGF 
secretion (Fig. 7). These data suggested that cigarette smoke 
may therefore promote the progression of prostate cancer 
through HO-1-modulated VEGF increase.
Previous studies reported that nuclear translocation of HO-1 
was associated with prostate cancer (19), and its nuclear expres-
sion had a strong correlation with the grade of differentiation of 
oral squamous cell carcinomas (28,29) and the tumor progression 
of head and neck squamous cell carcinomas (27). Together with 
our finding that SM induced nuclear translocation in prostate 
cancer, this suggested that SM-mediated nuclear localization 
of HO-1 is contributable to the progression of prostate cancer. 
Given that nuclear localization may be associated with the 
progression of prostate cancer, we asked whether nuclear HO-1 
was involved in the promotion of VEGF secretion in prostate 
cancer. To address this question we attempted to express HO-1 
exclusively in nuclei of cells by tagging it with tandem nuclear 
localization signals. Interestingly, ectopic expression of nuclear 
HO-1 had the potential to significantly induce VEGF transcrip-
tional activity and secretion, whereas cytoplasmic HO-1 did 
not (Fig. 6). Taken together, these findings strongly suggest that 
nuclear localization of HO-1 induced by cigarette smoke plays 
a central role in VEGF secretion and may contribute to tumor 
angiogenesis and the progression of prostate cancer.
Our study revealed the mechanism by which cigarette 
smoking is associated with prostate cancer through nuclear 
HO-1 and VEGF regulation. This study also provides new 
insights into the involvement of cigarette smoke and HO-1 in 
prostate cancer. Therapies targeting nuclear HO-1 may therefore 
represent a novel approach for the treatment of prostate cancer.
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